Diagnostics and Therapeutics for HIV: Global Markets - Tucson News Now

Diagnostics and Therapeutics for HIV: Global Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, April 28, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diagnostics and Therapeutics for HIV: Global Markets

http://www.reportlinker.com/p02100598/Diagnostics-and-Therapeutics-for-HIV-Global-Markets.html


STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing and prophylaxis of HIV/AIDS. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and considered assessment of the regulatory environment, health-care policies, demographics and other factors that directly affect the HIV/AIDS market. The wider economic environment is also taken into account.

REASONS FOR DOING THE STUDY

HIV/AIDS is one of the most catastrophic threats to human health throughout the world. Advanced treatment options and improved methods of diagnosis have helped to moderate the growth of the epidemic and this has presented opportunities for companies prepared to engage actively in this field. However, the management of HIV/AIDS is still, in many respects, an unfulfilled market and there is an ongoing, urgent need for promising new research directions as well as optimal exploitation of the treatment and diagnostic options already developed. In this dynamic and continually evolving marketplace, there is a need for an up-to-date, comprehensive appraisal covering both strategic and tactical options confronting the pharmaceutical industry.

INTENDED AUDIENCE

This report is intended for large companies, small and medium enterprises (SMEs), government organizations and nongovernmental organizations (NGOs) operating in the HIV/AIDS space. Specifically, this report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.

SCOPE AND FORMAT

This report summarizes the market of HIV/AIDS products and discusses the present status and evolution of antiretroviral (ARV) drugs with analyses by selected major national markets. The latest treatment and diagnostic options and practices are described and their cost implications clarified, especially in the context of treatment affordability in countries of widely varying economic status. The emergence of a considerable generic medicine component in the marketplace, alongside the presence of original branded medicines, is discussed. The current market for antiretroviral therapies is analyzed, with breakdowns by drug categories, and the leading drugs of 2012 are discussed. Five-year forecasts are provided with reasonable explanations. This report also summarizes the research efforts in early HIV prophylaxis, including pre-exposure prophylaxis, post-exposure prophylaxis and prevention of HIV transmission from mother to infant. Finally, major research efforts for developing HIV vaccines are summarized and promising directions are identified.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Primary research included interviews with leading individuals in pharmaceutical companies and industry associations. Primary sources of published data included company annual reports, SEC filings, and government and industry publications. Secondary sources consisted of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources and critically assessed by BCC Research. The global HIV market is estimated based on sales revenue generated by antiretroviral drugs.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected at 2013 dollar value without attempting to predict the effect of inflation/deflation. National market analyses and forecasts are provided for seven economically advanced countries and for five countries classified as of low to medium economic advancement.

Chapter- 1: INTRODUCTION - Complimentary 3

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE AND FORMAT
METHODOLOGY
ANALYST'S CREDENTIALS
INFORMATION SOURCES
MARKET ANALYSES AND FORECASTS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH ONLINE SERVICES
DISCLAIMER

Chapter- 2: SUMMARY 6

THE SKEWED MARKET
HIV THERAPEUTICS MARKET WILL BE WORTH $19.6 BILLION IN 2018
FIXED-DOSE COMBINATION DRUGS AND INTEGRASE INHIBITOR DRUGS WILL DRIVE THE MARKET
2013 WHO GUIDELINES WILL EXPAND THE GLOBAL HIV MARKET
STRICT ADHERENCE TO ARV TREATMENT REMAINS A CHALLENGE
DEMAND FOR ACCESS TO AFFORDABLE MEDICINE
SEVEN OF THE EIGHT LEADING ARV DRUGS ARE ON PATENT CLIFF
GILEAD SCIENCES WILL CONTINUE TO DOMINATE THE HIV THERAPEUTICS MARKET
POC DEVICES FOR CD4 AND VIRAL LOAD TESTING WILL DRIVE THE HIV DIAGNOSTICS MARKET
THE U.S. WILL REMAIN THE LEADING NATIONAL MARKET FOR HIV
EARLY PROPHYLAXIS IS THE KEY TO HIV MANAGEMENT
HIV VACCINES-A LONG ROAD AHEAD
TOWARDS AN AIDS-FREE GENERATION

Chapter- 3: OVERVIEW 8

GLOBAL BURDEN OF HIV
GLOBAL RESPONSE TO HIV EPIDEMIC
MILESTONES IN HIV RESEARCH
TARGETING HIV LIFECYCLE
DIAGNOSTIC TOOLS FOR DETECTING HIV INFECTION
EFFORTS FOR HIV PROPHYLAXIS
FUTURE OF GLOBAL HIV MARKET
CONCLUSION

Chapter- 4: GLOBAL MARKET 19

GLOBAL HIV MARKET 2012
GLOBAL HIV MARKET FORECAST TO 2018
HIV MARKET BY GEOGRAPHICAL REGIONS
NORTH AMERICAN HIV MARKET
EUROPEAN HIV MARKET
THE ASIAN HIV MARKET
HIV MARKET IN ROW
GLOBAL INVESTMENT IN HIV RESEARCH
GENERIC HIV DRUGS MARKET
CHAPTER SUMMARY

Chapter- 5: HIV THERAPEUTICS MARKET: LEADING ARV DRUG CATEGORIES 15

THERAPY BY LINE-TREATMENT
ARV MARKET BY DRUG CATEGORIES
CHAPTER SUMMARY

Chapter- 6: HIV THERAPEUTICS MARKET: LEADING DRUGS 17

LEADING EIGHT HIV DRUGS CLAIMED OVER 80% OF THE MARKET SHARE
PROMISING EMERGING THERAPIES
OTHER DRUGS
CHAPTER SUMMARY

Chapter- 7: ARV DRUGS PIPELINE ANALYSIS 15

NRTI DRUGS IN DEVELOPMENT
NNRTIS IN DEVELOPMENT
INTEGRASE INHIBITORS IN DEVELOPMENT
ENTRY INHIBITORS IN DEVELOPMENT
COMBINATION THERAPIES
PHARMACOKINETIC BOOSTERS IN DEVELOPMENT
EMERGING THERAPIES
CHAPTER SUMMARY
Figure 9 : NUMBER OF CLINICAL TRIALS BY DEVELOPMENTAL PHASE

Chapter- 8: HIV TESTING AND DIAGNOSTICS 22

EARLY DETECTION
PATIENT STAGING
TREATMENT SWITCHING
TYPES OF HIV TESTS
SELECTED RAPID HIV TESTS
SELECTED CD4 TESTS
SELECTED VIRAL LOAD TESTS
HIV DIAGNOSTICS PIPELINE
HIV DIAGNOSTICS MARKET
CHAPTER SUMMARY

Chapter- 9: HIV PROPHYLAXIS 12

HIV PROPHYLAXIS BASED ON EXPOSURE
EARLY PROPHYLAXIS
PRE-EXPOSURE PROPHYLAXIS
POST-EXPOSURE PROPHYLAXIS (PEP)
PREVENTING TRANSMISSION FROM MOTHER TO CHILD
CHAPTER SUMMARY

Chapter- 10: HIV VACCINES 7

HURDLES FOR DEVELOPING HIV VACCINES
PROPHYLACTIC VS. THERAPEUTIC HIV VACCINES
TYPES OF HIV VACCINES
THE HISTORIC RV144 TRIAL
RECENT ADVANCES IN HIV VACCINE RESEARCH
FUTURE HOPES OF A SUCCESSFUL HIV VACCINE

Chapter- 11: QUALITATIVE ANALYSIS 19

PORTER'S 5 ANALYSIS
CHALLENGES OF THE HIV MARKET
OPPORTUNITIES FOR REVENUE GENERATION
DRIVERS OF THE HIV MARKET
IMPLICATIONS OF RECENT REGULATORY GUIDELINES
RESTRAINTS TO THE GROWTH OF HIV MARKET
HARMONIZATION
CHAPTER SUMMARY

Chapter- 12: COMPANY PROFILES 12

HIV THERAPEUTICS-LEADING COMPANIES
HIV DIAGNOSTICS: LEADING COMPANIES
SELECTED EMERGING AND GENERIC COMPANIES IN THE GLOBAL HIV MARKET

Chapter- 13: APPENDIX A: GLOSSARY 5

Table 66 : GLOSSARY

Chapter- 14: APPENDIX B: DRUG ACRONYMS 1


Chapter- 15: APPENDIX C: ABBREVIATIONS 2

Table 67 : ABBREVIATIONS

List of Tables

Summary Table : GLOBAL HIV MARKET, THROUGH 2018
Table 1 : TOP 10 LEADING CAUSES OF DEATHS IN THE WORLD, 2011
Table 2 : BURDEN OF HIV BY GEOGRAPHICAL REGIONS
Table 3 : MILESTONES IN THE HISTORY OF HIV
Table 4 : LIFE CYCLE OF HIV-THERAPEUTICS TARGET POINTS
Table 5 : FORECASTED NUMBER OF PEOPLE RECEIVING ARV THERAPY, 2012-2018
Table 6 : ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, THROUGH 2018
Table 7 : ARV DRUGS MARKET SHARE BY GEOGRAPHIC REGIONS, 2012-2018
Table 8 : EUROPEAN COUNTRIES BY RATES OF HIV DIAGNOSIS
Table 9 : PATTERN OF HIV INFECTION BY EUROPEAN REGIONS, 2012
Table 10 : SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES, THROUGH 2018
Table 11 : HIV THERAPEUTICS MARKET SHARE BY EU5 COUNTRIES, 2012-2018
Table 12 : HIV PREVALENCE IN EU5 COUNTRIES, 2012
Table 13 : RATE OF LATE DIAGNOSIS BY REGIONS OF THE U.K.
Table 14 : HIV PREVALENCE AND INCIDENCE OF NEW INFECTIONS IN ASIAN COUNTRIES, 2012
Table 15 : SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, THROUGH 2018
Table 16 : HIV MARKET SHARE BY LEADING ASIAN COUNTRIES, 2012-2018
Table 17 : FORECAST GLOBAL ANNUAL INVESTMENT IN HIV RESEARCH, THROUGH 2018
Table 18 : GLOBAL INVESTMENT SHARE BY AREA OF RESEARCH, 2012-2018
Table 19 : INVESTMENT BY DONOR TYPE
Table 20 : INVESTMENT IN HIV THERAPEUTICS BY DRUG SUBCATEGORIES IN 2012
Table 21 : INVESTMENT BY MODE OF HIV PROPHYLAXIS
Table 22 : LEADING ARV DRUGS ON PATENT CLIFF
Table 23 : DRIVERS AND RESTRAINTS OF GENERIC HIV MARKET
Table 24 : DRIVERS AND RESTRAINTS OF GLOBAL HIV MARKET
Table 25 : RECOMMENDED ARV TREATMENT BY THE WHO
Table 26 : HIV THERAPEUTICS MARKET BY DRUG CATEGORY, THROUGH 2018
Table 27 : HIV THERAPEUTICS MARKET SHARE BY DRUG CATEGORY, 2012-2018
Table 28 : LIST OF APPROVED NRTIS
Table 29 : LIST OF APPROVED NNRTIS
Table 30 : LIST OF APPROVED PROTEASE INHIBITORS
Table 31 : LIST OF APPROVED INTEGRASE INHIBITOR DRUGS
Table 32 : LIST OF APPROVED ENTRY INHIBITORS
Table 33 : LIST OF APPROVED STR FDC DRUGS
Table 34 : MARKET DRIVERS AND RESTRAINTS OF ARV DRUGS, BY CLASS
Table 35 : SALES REVENUE FORECAST OF LEADING HIV DRUGS, THROUGH 2018
Table 36 : HIV MARKET SHARE BY LEADING DRUGS
Table 37 : MARKET DRIVERS AND RESTRAINTS OF THE LEADING ARV DRUGS
Table 38 : ONGOING CLINICAL TRIALS OF NNRTI DRUGS IN DEVELOPMENT
Table 39 : ONGOING CLINICAL TRIALS OF STR FDC DRUGS
Table 40 : ONGOING CLINICAL TRIALS OF EMERGING THERAPIES
Table 41 : OVERVIEW OF ARV DRUGS IN DEVELOPMENT
Table 42 : HIV RAPID TESTS ADVANTAGES AND DISADVANTAGES BY CLIA* COMPLEXITY AND GENERATION
Table 43 : FDA APPROVED ANTIBODY HIV TESTS
Table 44 : FDA APPROVED ANTIGEN-ANTIBODY COMBO TESTS
Table 45 : CD4 TESTS IN THE MARKET
Table 46 : LIST OF MARKETED VIRAL LOAD TESTS
Table 47 : HIV/AIDS DIAGNOSTICS PIPELINE
Table 48 : HIV DIAGNOSTICS MARKET BY TYPES OF TESTS, THROUGH 2018
Table 49 : HIV DIAGNOSTICS MARKET SHARE BY TYPES OF TESTS, 2012-2018
Table 50 : CD4 TESTING MARKET SHARE IN SEVEN SUB-SAHARAN AFRICAN COUNTRIES, 2012
Table 51 : GLOBAL DEMAND FOR CD4 TESTING, 2012-2018
Table 52 : GLOBAL DEMAND FOR VIRAL LOAD TESTING, 2012–2018
Table 53 : MARKET DRIVERS AND RESTRAINTS FOR HIV TESTING PRODUCTS
Table 54 : CLINICAL TRIALS TESTING DRUG-BASED PrEP, 2014 AND 2015
Table 55 : ONGOING CLINICAL TRIALS OF MICROBICIDES, 2014 AND 2015
Table 56 : EVOLUTION OF WHO GUIDELINES WITH REGARDS TO PMTCT, 2006-2013
Table 57 : SELECTED ON-GOING TRIALS ON PMTCT, 2013-2017
Table 58 : TYPE OF HIV VACCINES
Table 59 : ONGOING CLINICAL TRIALS OF PROPHYLACTIC HIV VACCINES
Table 60 : ONGOING CLINICAL TRIALS FOR THERAPEUTIC HIV VACCINES
Table 61 : RETENTION TO TREATMENT
Table 62 : FIRST-LINE VS. SECOND-LINE TREATMENT MEDIAN PRICE, 2012
Table 63 : CHALLENGES AND OPPORTUNITIES IN THE GLOBAL HIV MARKET
Table 64 : MAJOR DRIVERS AND RESTRAINTS IN THE GLOBAL HIV MARKET
Table 65 : HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES, 2012-2018
Table 66 : GLOSSARY
Table 67 : ABBREVIATIONS

List of Figures

Summary Figure : GLOBAL HIV MARKET, 2012-2018
Figure 1 : ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, 2012-2018
Figure 2 : SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES
Figure 3 : SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, 2012-2018
Figure 4 : GENERIC VS. BRANDED ARV DRUGS GLOBAL SALES REVENUE, 2012-2018
Figure 5 : GENERIC ARV DRUGS GLOBAL SALES REVENUE GROWTH
Figure 6 : HIV THERAPEUTICS MARKET BY DRUG CATEGORY 2012-2018
Figure 7 : HIV MARKET SHARE BY LEADING DRUGS
Figure 8 : RANKING (BY MARKET SHARE) OF LEADING ARV DRUGS, 2012-2018
Figure 9 : NUMBER OF CLINICAL TRIALS BY DEVELOPMENTAL PHASE
Figure 10 : GLOBAL HIV THERAPEAUTICS MARKET ANALYSIS
Figure 11 : HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES


To order this report: Diagnostics and Therapeutics for HIV: Global Markets
http://www.reportlinker.com/p02100598/Diagnostics-and-Therapeutics-for-HIV-Global-Markets.html



__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow